Kitov Pharma is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

Kitov’s flagship combination drug, Consensi™, is indicated to treat osteoarthritis pain and hypertension simultaneously. After Consensi™ achieved the primary efficacy endpoint for its Phase III clinical trial in December 2015, Kitov submitted a New Drug Application (NDA) in July 2017. The U.S. Food & Drug Administration (FDA) approved Consensi™ for marketing on May 31, 2018.

Kitov's newest drug, NT-219, which is developed by its majority-owned subsidiary, TyrNovo, is an innovative, patented small molecule targeting IRS1/2 and STAT3 – two signal proteins that are part of an anti-cancer drug resistance mechanism. In various preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efficacy in preventing acquired resistance and reversing tumor resistance was demonstrated.

By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver a rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives.


Combination drug for treatment of osteoarthritis pain and hypertension approved by U.S. FDA for marketing

Consensi™ is a combination drug that is indicated for the treatment of osteoarthritis pain and hypertension simultaneously. In December 2015, it was announced that the Phase III clinical trial for Consensi™ successfully met its primary efficacy endpoint. The U.S. FDA approved Consensi™ for marketing on May 31, 2018.


Novel patented small molecule designed to
overcome cancer drug resistance

NT219 is an innovative, first-in-class, small molecule that presents a new concept in cancer therapy by promoting the degradation and inhibiting the phosphorylation of two oncology-related signal transducers, Insulin Receptor Substrates (IRS) 1/2 and signal transducer and activator of transcription 3 (STAT3), respectively. While targeted anti-cancer drugs inhibit the "ON" signal, NT219 activates the "OFF" switch, extensively blocking major oncogenic pathways. In pre-clinical trials, NT219, in combination with several approved cancer drugs, displayed potent anti-tumor effects and increased survival in various cancers, including sarcoma, melanoma, pancreatic, lung, head & neck, prostate and colon cancers, by preventing the tumors from developing drug resistance and reversing resistance after it had been acquired. NT219 is licensed from Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem.